Neurogene Inc (NAS:NGNE)
$ 39.54 -3.21 (-7.49%) Market Cap: 788.84 Mil Enterprise Value: 556.99 Mil PE Ratio: 0 PB Ratio: 2.60 GF Score: 12/100

Neurogene Inc at TD Cowen Healthcare Conference Transcript

Mar 4, 2026 / 03:30 PM GMT
Release Date Price: $23.91 (+8.73%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NGNE.OQ - Neurogene Inc
Neurogene Inc at TD Cowen Healthcare Conference
Mar 04, 2026 / 03:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you everyone for joining us for the Neurogene Fireside chat here at the forty-sixth annual TD Cowan Healthcare Conference. I'm covering analyst Ritu Bal, and joining me today, we have founder and CEO Rachel McMinn. Rachel, thanks for joining us today.

So Neurogene is developing 401, gene therapy for RET syndrome, based on your exact regulated expression gene regulated expression gene therapy platform. For those unfamiliar, could you briefly walk us through the exact platform and how 401 is differentiated?

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Sure. Well, I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot